Regeneron CSO George Yancopoulos on testing Dupixent to reverse allergies

SAN FRANCISCO — While Dupixent could add a major new indication in COPD this year, Regeneron’s longtime top scientist is already excited by the next bold idea for its immunology blockbuster.

George Yancopoulos, Regeneron’s chief scientific officer, said Dupixent’s potential to reverse severe allergies is the “next…
Click here to view original post